Green light for Novartis’ lung cancer combination therapy

23rd June 2017 Uncategorised 0

Novartis’ combination therapy Tafinlar + Mekinist has won approval from the US Food and Drug Administration to treat patients with metastatic non-small cell lung cancer (NSCLC) carrying the BRAF V600E mutation.

More: Green light for Novartis’ lung cancer combination therapy
Source: News